Nabgen Inc.

Funding and NIH signals

• NIH award NIH awarded $1.01M (STTR Phase II 5R42TR004338-03, continuation, notice Aug 25, 2026); 2 NIH awards totaling $1.33M in the last 12 months. NIH RePORTER 5R42TR004338-03 (Aug 25, 2026)
  Evidence (2 events)

  • Aug 25, 2026 · NIH RePORTER 5R42TR004338-03
    Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 5R42TR004338-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1014676; Administering IC: National Center for Advancing Translational Sciences; Project title: Novel strategy to block AAV neutralizing antibody activity; Organization type: Domestic For-Profits
  • Jul 8, 2026 · NIH RePORTER 1R41TR006064-01
    Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 1R41TR006064-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 312461; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a universal approach to block inhibitors for protein replacement therapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals